The curative action of hexamethylmelamine on intramuscularly or intracerebrally implanted Yoshida sarcoma.
Curative effects of hexamethylmelamine (HMM, NSC 13875) against intramuscularly or intracerebrally implanted Yoshida sarcoma depend on the schedules. A twice daily oral administration over a 2-week period showed a significant chemotherapeutic advantage over a single daily administration. The observed curative effect depends on the tumour site and on its mass. The Yoshida sarcoma seems to be one of the most suitable test models for HMM or related derivatives.
D006585:Altretamine / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012517:Sarcoma, Yoshida / Q000188:drug therapy*; D014227:Triazines / Q000627:therapeutic use*
D014227:Triazines; D006585:Altretamine